Filippo CARACI

Professore associato di Farmacologia [BIO/14]

E’ Ricercatore a tempo determinato (RTDb) presso il Dipartimento di Scienze del Farmaco dell’Università degli Studi Catania ed è Responsabile Scientifico della convenzione di ricerca nel settore della Neuropsicofarmacologia tra I'IRCCS Oasi Maria SS di Troina e I'Università di Catania dall’1-1-2012. Insegna Farmacologia nel Corso di Laurea magistrale in Psicologia, Tossicologia nel Corso di Laurea in Chimica e Tecnologia Farmaceutiche, Fitoterapia nel Corso di Laurea in Scienze Farmaceutiche applicate dell’Università degli Studi di Catania e Farmacogenetica nel Master in discipline regolatorie del Farmaco presso l’Università degli Studi di Catania. Dal 2006 al 2011 ha insegnato Neurofarmacologia Clinica presso la Scuola di Specializzazione in Farmacologia dell’Università di Roma “La Sapienza” e attualmente insegna nelle scuole di specializzazione in Geriatria e “Farmacogenetica e Farmacogenomica” e “Terapie delle malattie del Sistema Nervoso Centrale: aspetti farmaco terapeutici”  presso la Scuola  di Specializzazione in Farmacia Ospedaliera dell’Università degli Studi  di Catania.

E’ membro dell’American Society for Neuroscience, dello European College of Neuropsychopharmacology, della Società Italiana di Farmacologia, della Società Italiana di Psichiatria e della Società Italiana di Neuropsicofarmacologia.  E’ autore di oltre 110 pubblicazioni su riviste internazionali a comitati di referee in diverse aree della neurofarmacologia e delle neuroscienze. E’ Associate Editor di Frontiers in Pharmacology,  Membro dell’Editorial Board di  CNS & Neurological Disorders - Drug Targets e Associate Faculty Member nell’area Mood Disorders per la rivista F1000 Prime.

Nella sua attività scientifica ha approfondito le basi neurobiologiche e genetiche della depressione e della malattia di Alzheimer al fine di identificare nuovi target farmacologici. E’ autore del Progetto Nazionale Interdrugs finalizzato allo studio delle interazioni clinicamente significative in psichiatria. Negli ultimi anni ha partecipato in qualità di docente a differenti corsi ECM sulle interazioni farmacologiche e sulle basi neurobiologiche ed il trattamento farmacologico di malattie neuropsichiatriche quali la schizofrenia, la depressione, il dolore cronico e le demenze.

Ha recentemente svolto nel 2013 e nel 2019 l’attività di visiting professor presso il Department of Pharmacology and Therapeutics  della   McGill  University, Montreal e nel 2014 presso il Centro de Investigacion Principe Felipe, Valencia, Spagna. Nel 2015 ha svolto il ruolo Visiting Researcher a Bordeaux,  presso il Neurocentre Magendie, INSERM U862, Pathophysiology of Neural plasticity, Université Bordeaux, Francia sotto la supervisione del Prof. Piazza, dove ha  studiato il ruolo dell’abuso di cannabis come fattore di rischio per le psicosi e le basi molecolari del declino cognitivo nella sindrome di Down. Dal 2-2-2016 all’1-4-2016 ha svolto il ruolo di Visiting Professor presso l’Università di Bordeaux in qualità di vincitore del Grant internazionale IDEX Visiting Scholar 2016-“Initiative of Excellence” Program dell’Università di Bordeaux. Ha nuovamente ottenuto la  stessa posizione di Visiting Scholar per il 2017 dal 13-2 al 13-3 presso il Neurocentre Magendie INSERM U1215 dell’Università di Bordeaux. Il 12-4-2017 ha ottenuto l’Abilitazione Scientifica Nazionale alla posizione alla funzione di professore di seconda fascia ed il 6-11-2018 l’Abilitazione Scientifica Nazionale alla posizione alla funzione di professore di prima fascia per il settore concorsuale 05/G1 – Farmacologia, farmacologia clinica e farmacognosia.

Dal 16-1-2018 svolge il ruolo di Coordinatore e responsabile dei  programmi di ricerca della linea 4 “I disturbi cognitivi e le malattie neurodegenerative: identificazione di nuovi biomarcatori e di nuovi target farmacologici”.” presso I'IRCCS Oasi Maria SS di Troina . Dal 26-11-2018 è referente del Dipartimento di Scienze del Farmaco nel Consiglio della Scuola Superiore di Catania,Centro di alta formazione e struttura didattica speciale dell’Università degli Studi di Catania inserita nella rete italiana delle Scuole di Eccellenza di alta qualificazione. Dal 9-1-2019 è stato nominato componente dell’Organismo per il benessere e la protezione Animale (OPBA) dell’Università degli Studi di Catania.

Dal 16-12-2019 è stato nominato, con D.R.3979, Delegato del Rettore al Trasferimento Tecnologico ed ai Rapporti con le Imprese-Ambito Biomedico.

 

1) Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, Nicoletti F. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci. 24(5): 233-8, 2003, Elsevier, Oxford, UK;

 

2) Bosco P, Gueant-Rodriguez RM, Anello G, Barone C, Namour F, Caraci F, Romano A, Romano C, Gueant JL. Methionine synthase (MTR) 2756 (A --> G) polymorphism, double heterozygositymethionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, andelevated homocysteinemia are three risk factors for having a child with Down syndrome. Am J Med Genet Part A, 121A(3): 219-24, 2003, Wiley, Salt Lake City, USA.;

 

3) Caraci F, Chisari M, Frasca G, Chiechio S, Salomone S, Pinto A, Sortino MA, Bianchi A.  Effects of phenformin on the proliferation of human tumor cell lines. Life Sci.; 74(5): 643-50, 2003 Elsevier, Oxford, UK.;

 

4) Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, Colucci D'Amato C. Role of magnesium, coenzyme Q10, riboflavin and vitamin B12  in migraine prophylaxis. Vitamins and Hormones; 69:297-312, 2004, Elsevier, Oxford, UK.;

 

5) Anello G, Gueant-Rodriguez R-M, Bosco P, Gueant J-L, Romano A, Namour B, Spada RS,  Caraci F, Pouriè G, Daval J-L, Ferri R. Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer’s disease, Neuroreport, 15(5): 859-61, 2004, Lippincott Wiiliams & Walkins, London, UK.;

 

6) Bosco P, Gueant-Rodriguez R-M, Anello G, Romano A, Namour B, Spada RS, Caraci F,  Trincali G, Ferri R, and Gueant J-L. Association of IL-1 RN 2* allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer’s disease, Journal of Neurology, Neurosurgery & Psichiatry; 75(7):1036-8, 2004, BMJ Journals, London, UK.;

 

7) Caricasole A, Copani A, Caraci F, Aronica E,  Rozemuller A.J., Caruso A, Storto M,  Gaviraghi G, Terstappen GC,  Nicoletti F. Induction of  Dickkopf-1, a negative modulator of  the Wnt pathway, is associated with  neuronal degeneration in Alzheimer’s brain. Journal of Neuroscience, 24 (26):6021-7, 2004, American Society of Neuroscience, Washington, USA.;

 

8) Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport.; 16(11):1223-6, 2005,  Lippincott Williams & Walkins, London, UK.

 

9) Caraci F, Chisari M, Frasca G, Canonico PL, Battaglia A, Calafiore M, Battaglia G, Bosco P,  Nicoletti F, Copani A, Sortino MA.  Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. Brain Res.; 1047(1):30-7, 2005, Elsevier, Oxford, UK;

 

10) Bosco P, Gueant-Rodriguez RM, Anello G, Spada RS, Romano A, Caraci F, Ferri R, Gueant JL.  Allele epsilon 4 of APOE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neurosci Lett; 388(3):168-72, 2005, Elsevier, Oxford, UK.;

 

11) Calafiore M, Battaglia G, Zappala A, Trovato-Salinaro E, Caraci F, Caruso M, Vancheri C, Sortino MA, Nicoletti F, Copani A.  Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid. Neurobiol Aging;  27 (4): 606-13, 2006, Elsevier, Oxford, UK.;

 

12) Caruso A, Motulese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, Terstappen GC, Gaviraghi G and Caricasole A. Inhibition of tha canonical Wnt signalling pathway by apolipoprotein E4 in PC12 cells. Journal of Neurochemistry, 98 (2): 364-371, 2006, Blackwell Publishing Oxford, UK.;

 

13) Bosco P, Gueant-Rodriguez RM, Anello G, Spada RS, Romano A, Fajardo A, Caraci F,  Ferri R, Gueant JL. "Association of homocysteine (but not  of MTHFR 677 C>T,  MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischemic cerebrovascular disease in Sicily" Thrombosis and Haemostasis, 96 (2) 54-9,  2006, Blackwell Publishing Oxford, UK;

 

14) Scali C, Caraci F *, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G, Copani A, Nicoletti F, Terstappen GC, Caricasole A.  Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1 Neurobiology of disease 24 (2) 254-265, 2006 Elsevier, Oxford, UK. (* equal contribution);

 

15) Copani A, Hoozemans JJ, Caraci F, Calafiore M, Van Haaster ES, VeerhiusR, Rozemuller AJM, Aronica E, Sortino MA, Nicoletti F. DNA polymerase-ß is early expressed in neurons of Alzheimer’s Disease brain and  is loaded into DNA replication forks ni neurons challenged with ß-amyloid, Journal of Neuroscience, 26 10949-57, 2006 American Society of Neuroscience, Washington, USA;

 

16) Copani A, Caraci F, Hoozemans JJ, Calafiore M, Angela Sortino M, Nicoletti F. The nature of the cell cycle in neurons: Focus on a "non-canonical" pathway of DNA replication causally related to death. Biochim Biophys Acta.; 1772(4):409-12, 2007 Elsevier, Oxford, UK.;

 

17) Bosco P, Caraci F*, Copani A, Spada RS, Sortino MA, Salluzzo R, Salemi M, Nicoletti F, Ferri R. The CDC2 I-G-T haplotype associated with the APOE varepsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily. Neurosci Lett. 419 (3):195-8. 2007 , Elsevier, Oxford, UK (* equal contribution);

 

18) Salemi M, Romano C, Ragusa L, Di Vita G, Salluzzo R, Oteri I, Trovato ML, Romano C, Caraci F, Nicoletti F, Bosco P. A new 6-bp SOX-3 polyalanine tract deletion does not segregate with mental retardation. Genet Test.;11(2):124-7, 2007; Mary Ann Liebert, Inc. Publishers, New York, USA;

 

19) Cosentino FI, Bosco P, Drago V, Prestianni G, Lanuzza B, Iero I, Tripodi M, Spada RS, Toscano G, Caraci F, Ferri R. The APOE epsilon4 allele increases the risk of impaired spatial working memory in obstructive sleep apnea. Sleep Med. ; 9(8):831-9, 2008 Elsevier, Oxford, UK;

 

20) Caraci F.,  Battaglia G., C. Busceti, F. Biagioni, F. Mastroiacovo, P. Bosco, GM Leggio, F. Drago, F. Nicoletti, MA Sortino and A. Copani. TGF-β1 protects against Aβ-neurotoxicity  via the phosphatidylinositol-3-kinase pathway. Neurobiology of disease. 30(2):234-42, 2008, Elsevier, Oxford, UK;

 

21) Caraci F., Gili E., Calafiore M., Failla , La Rosa C., Crimi N., Sortino M.A., Nicoletti F., Copani A., Vancheri C. TGF-b1 targets the GSK-3b/b-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacological Research. 57 (4):274-82, 2008,  Elsevier, Amsterdam, The Netherlands;

 

22) Caraci F, Busceti C, Biagioni F, Aronica E, Mastroiacovo F, Cappuccio I, Battaglia G, Bruno V, Caricasole A, A, Nicoletti F. The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders. Neurochemical Research. 33(12):2401-6, 2008, Springer, Chennai, India;

 

23) Copani A, Guccione S, Giurato L, Caraci F, Calafiore M, Sortino MA, Nicoletti F. The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development. Current  Medicinal Chemistry ; 15(24):2420-32, 2008, Bentham Science Publishers, Bussum, The Netherlands;

 

24) De Bona P., Giuffrida M. L., Caraci F., Copani A., Pignataro B., Attanasio F., Cataldo S., Pappalardo G. and Rizzarelli E. Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Aβ(1–42) fibrillogenesis and toxicity. Journal of Peptide Science, 15(3):220-8, 2009; Wiley Publishers,  Chichester, UK;

 

25) Carbonaro V., Caraci F., Giuffrida L., Merlo S., Canonico PL, Drago F., Copani A., Sortino M.A. Enhanced expression of ERa in astrocytes modifies the response  of cortical neurons to β-amyloid toxicity. Neurobiology of disease;  33(3):415-21, 2009.  Elsevier, Oxford, UK;

 

26) Chiechio S., Zammataro M., Caraci F., Rampello L., Copani A., Sabato a., and Nicoletti F.  Pregabalin in the treatment of chronic pain: an overview. Clinical drug Investigation, 29 (3) 203-213, 2009; doi: 10.2165/00044011-200929030-00006; Adis a Wolters Kluwer Business; UK;

 

27) Salemi M, Romano C, Barone C, Calí F, Caraci F, Romano C, Scavuzzo C, Scillato F, Salluzzo MG, Piccione M, Martines M, Corsello G, Nicoletti F, Bosco P. SPANX-B and SPANX-C (Xq27 region) gene dosage analysis in Down's syndrome subjects with undescended testes. J Genet. 2009; 88(1):93-7. Springer, Sadashivanagar, India;

 

28) Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. Beta-amyloid monomers are neuroprotective. J Neurosci. 2009; 29:10582-7. American Society of Neuroscience, Washington, USA;

 

29) Salomone S, Caraci F, Capasso A. Migraine: an overview. Open Neurol J. 2009; 3:64-71. Bentham Science Publishers, Bussum, The Netherlands;

 

30) Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease:  neurobiological links and common pharmacological targets. Eur J Pharmacol. 2010; 626(1):64-71. Elsevier, Oxford, UK;

 

31) Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci. 2010;21(2):83-93. Freund Publishing House, Tel Aviv, Israel;

 

32) Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of  Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 2010 20(11):747-65. Elsevier, Oxford, UK;

 

33) Carta MG, Aguglia E, Bocchetta A, Balestrieri M, Caraci F, Casacchia M, Dell'osso L, Sciascio GD, Drago F, Faravelli C, Lecca ME, Moro MF, Morosini PL, Nardini M, Palumbo G, Hardoy MC. The use of antidepressant drugs and the lifetime prevalence of major depressive disorders in Italy. Clin Pract Epidemiol Ment Health. 2010; 6:94-100. Bentham Science Publishers, Bussum, The Netherlands;

 

34) Caraci F.,  Battaglia G., Bruno V., Bosco, Carbonaro V, Giuffrida ML, Drago F. Sortino M.A. Nicoletti F., Copani A. TGF-β1 pathway as a new target for neuroprotection in Alzheimer’s disease.

CNS Neuroscience & Therapeutics; 17 (4): 237-249, 2011 ; Blackwell Publishing Oxford, UK pubblicato online nel 2009 (doi: doi: 10.1111/j.1755-5949.2009.00115.x. Epub 2009 Nov 19);

 

35)  Matrisciano F, Busceti CL , Bucci D,  Orlando RM, Caruso A, Molinaro G, Cappuccio I, Riozzi B, Gradini R, Motolese M, Caraci F, Copani A, Scaccianoce S, Melchiorri D, Bruno V, Battaglia G, Nicoletti F. Induction of the Wnt antagonist, Dickkopf-1, is involved in stress-induced hippocampal damage. PLOS ONE;2011 http://dx.plos.org/10.1371/journal.pone.0016447. Publications Manager, ONE; Public Library of Science, San Francisco, USA;

 

36) Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B,Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, Copani A, Nicoletti F. Targeting group-II metabotropic glutamate receptors for the treatment of psychosis associated with Alzheimer’s disease: selective activation of mGlu2 receptors amplifies b-amyloid toxicity in cultured neurons whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Molecular Pharmacology 2011 79:618-626. American Society for Pharmacology and Experimental Therapeutics, Bethesda, USA;

 

37) Caraci F, Pistarà V, Corsaro A, Tomasello ., Giuffrida ML, Sortino MA, Nicoletti F & Copani A. Neurotoxic properties of the anabolic androgenic steroids, nandrolone and methandrostenolone, in primary neuronal cultures. Journal of Neuroscience Research  2011 Wiley Publishers,  Chichester, UK doi: 10.1002/jnr.22578.

 

38) Caraci F, Crupi R, Drago F, Spina E. Metabolic Drug Interactions between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Curr Drug Metab. 2011; 12:570-77.

 

39) Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, Drago F, Nicoletti F & Copani A. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell and Tissue Research 2011 Springer, Bagacay, Dumaguete City, Philippines, DOI 10.1007/s00441-011-1230-6.

 

40) Spampinato SF, Molinaro G, Merlo S, Iacovelli L, Caraci F, Battaglia G, Nicoletti F, Bruno V, Sortino MA. Estrogen Receptors and Type-1 Metabotropic Glutamate Receptors are Interdependent in Protecting Cortical Neurons against {beta}-amyloid Toxicity. Molecular Pharmacology 2011 doi:10.1124/mol.111.074021 American Society for Pharmacology and Experimental Therapeutics, Bethesda, USA

 

41) Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M, Crimi N, Vancheri  C. Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms. PLoS One. 2011;6(10):e24663; doi:10.1371/journal.pone.0024663, Publications Manager, ONE; Public Library of Science, San Francisco, USA;

 

42) Carta MG, Tondo L, Balestrieri M, Caraci F, Dell'osso L, Di Sciascio G, Faravelli C, Hardoy MC, Lecca ME, Moro MF, Bhat KM, Casacchia M, Drago F. Sub-threshold depression and antidepressants use in a community sample: searching anxiety and finding bipolar disorder. BMC Psychiatry. 2011 Oct 10;11(1):164. doi:10.1186/1471-244X-11-164.

 

43) Carta MG, Aguglia E, Balestrieri M, Calabrese JR, Caraci F, Dell'osso L, Di Sciascio G, Drago F, Faravelli C, Lecca ME, Moro MF, Nardini M, Palumbo G, Hardoy MC. The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. J Affect Disord. 2011 Oct 24. doi:10.1016/j.jad.2011.09.041.

 

44) Salomone S, Caraci F*, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs. Br J Clin Pharmacol. 2011 Oct 28. doi: 10.1111/j.1365-2125.2011.04134.x; (* equal contribution).

 

45) Salemi M, Barone C, Romano C, Ridolfo F, Gulotta E, Scavuzzo C, Salluzzo MG, Giambirtone M, Caraci F, Romano C, Bosco P. Differential expression of PARP1 mRNA in leucocytes of patients with Down's syndrome. J Genet. 2011; 90(3):469-72.

 

46) Caraci F., Bosco P, Signorelli M, Spada RS, Cosentino FI, Toscano G, Bonforte C, Muratore S, Prestianni G, Panerai S, Giambirtone MC, Gulotta E, Romano C, Salluzzo MG, Nicoletti F,  Copani A, Drago F, Aguglia E and Ferri R. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer’s disease and is associated with AD-related depression. Eur Neuropsychopharmacol. 2012, 22(4):281-9, Elsevier, Oxford, UK;

 

47) Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012 Jan 1;26(1):39-67. doi: 10.2165/11594710-000000000-00000.

 

48) Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic? Neurochem Int. 2012 Jan 25. doi: 10.1016/j.neuint.2012.01.017

 

49) Salemi M, Barone C, Romano C, Ridolfo F, Salluzzo R, Scillato F, Scavuzzo C, Caraci F, Calogero AE, Romano C, Bosco P. Expression of LDOC1 mRNA in leucocytes  of patients with Down's syndrome. J Genet. 2012 Apr;91(1):95-8.

 

50) Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A. Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease. Mol Neurobiol. 2012 Aug 12.doi: 10.1007/s12035-012-8313-6.

 

51) Caraci F, Leggio GM, Drago F, Salomone S. Epigenetic drugs for Alzheimer's Disease: hopes and challenges. Br J Clin Pharmacol. 2012 Aug 21. doi: 10.1111/j.1365-2125.2012.04443.x.

 

52) Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, Turrini  R, Caraci F, Copani A, Battaglia G, Nicoletti F, Bruno V. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res. 2012 Oct 13;67:1-9. doi: 10.1016/j.phrs.2012.10.004.

 

53) Carta MG, Aguglia E, Caraci F, Dell'osso L, Sciascio GD, Drago F, Giudice ED,  Faravelli C, Hardoy MC, Lecca ME, Moro MF, Calò S, Casacchia M, Angermeyer M, Balestrieri M. Quality of life and urban / rural living: preliminary results of a community survey in Italy. Clin Pract Epidemiol Ment Health. 2012;8:169-74. doi:  10.2174/1745017901208010169.

 

54) Caraci F, Drago F. New definition of addiction proposed by the American Society of Addiction Medicine: Which implications for the treatment of tobacco dependence? Eur Neuropsychopharmacol. 2013 Jun 15. doi:pii: S0924-977X(13)00147-8. 10.1016/j.euroneuro.2013.05.003.

55)  Malaguarnera M, Drago F, Malaguarnera G, Li Volti G, Salomone S, Caraci F, Galvano F, Vacante M, Bucolo C, Malaguarnera M. Metal fume fever. Lancet. 2013 Jun 29;381(9885):2298. doi: 10.1016/S0140-6736(13)60689-3.

 

56) Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F*, Drago F*. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013 Jul 18. doi:pii: S0014-2999(13)00544-X. 10.1016/j.ejphar.2013.07.022.*Co-last authors.

 

57) Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, Salomone S. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr Top Med Chem. 2013;13(15):1853-63.

 

58) Salemi M, Barone C, Romano C, Salluzzo R, Caraci F, Cantarella RA, Salluzzo MG, Drago F, Romano C, Bosco P. Pericentrin expression in Down's syndrome. Neurol Sci. 2013 Nov;34(11):2023-5. doi: 10.1007/s10072-013-1529-z.

 

59) Bosco P; Ferri R.; Salluzzo MG; Castellano S; Signorelli M; Nicoletti, F; Di Nuovo S; Drago F; Caraci F. Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment, 2013, Current Genomics, 14 (2): 147-156.

60) Caraci F, Castellano S, Salomone S, Drago F, Bosco P, Di Nuovo S. Searching for Disease-Modifying Drugs in AD: Can We Combine Neuropsychological Tools with Biological Markers? CNS Neurol Disord Drug Targets. 2014 Feb;13(1):173-86.

 

61) Carta MG, Massidda D, Moro MF, Aguglia E, Balestrieri M, Caraci F, Dell'Osso L, Di Sciascio G, Drago F, Faravelli C, Hardoy MC, Calò S, Pollice R, Fortezzo A, Akiskal H. Comparing factor structure of the Mood Disorder Questionnaire (MDQ): In Italy sexual behavior is euphoric but in Asia mysterious and forbidden. J Affect Disord. 2014 Feb;155:96-103. doi: 10.1016/j.jad.2013.10.030.

62) Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxid Med Cell Longev. 2014;2014:313570. doi: 10.1155/2014/313570.

63) Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905. doi: 10.1371/journal.pone.0096905.

 

64) Orlando R, Borro M, Motolese M, Molinaro G, Scaccianoce S, Caruso A, di Nuzzo  L, Caraci F, Matrisciano F, Pittaluga A, Mairesse J, Simmaco M, Nisticò R, Monn JA, Nicoletti F. Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740. Neuropharmacology. 2014; 86:133-44. doi: 10.1016/j.neuropharm.2014.07.009.

 

65) Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S,  Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014 May 5;14(5):e11608. doi: 10.5812/hepatmon.11608.

 

66) Malaguarnera G, Gagliano C, Giordano M, Salomone S, Vacante M, Bucolo C, Caraci F, Reibaldi M, Drago F, Avitabile T, Motta M. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy.  Biomed Res Int. 2014;2014:191497. doi: 10.1155/2014/191497.

 

67) Carta MG, Preti A, Moro MF, Aguglia E, Balestrieri M, Caraci F, Dell'Osso L, Di Sciascio G, Drago F, Faravelli C, Hardoy MC, D'Aloja E, Cossu G, Calò S, Palumbo G, Bhugra D. Eating disorders as a public health issue: prevalence and attributable impairment of quality of life in an Italian community sample. Int Rev Psychiatry. 2014; 26(4):486-92. doi: 10.3109/09540261.2014.927753

 

68) Leggio GM, Torrisi SA, Castorina A, Platania CB, Impellizzeri AA, Fidilio A, Caraci F, Bucolo C, Drago F, Salomone S. Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. Eur Neuropsychopharmacol. 2014 doi: 10.1016/j.euroneuro.2014.11.004.

 

69) Carta MG, Moro MF, Aguglia E, Balestrieri M, Caraci F, Dell'Osso L, Di Sciascio G, Drago F, Hardoy MC, D'Aloja E, Machado S, Roncone R, Faravelli C. The attributable burden of panic disorder in the impairment of quality of life in a national survey in Italy. Int J Soc Psychiatry. 2015  pii:0020764015573848

 

70) Carta MG, Norcini-Pala A, Moro MF, Balestrieri M, Caraci F, Dell'Osso L, Sciascio GD, Faravelli C, Hardoy MC, Aguglia E, Roncone R, Nardi AE, Drago F. Does Mood Disorder Questionnaire identify sub-threshold bipolarity? Evidence studying worsening of quality of life. J Affect Disord. 2015; 183:173-8. doi: 10.1016/j.jad.2015.04.058.

 

71) Caraci F, Gulisano W, Guida CA, Impellizzeri AA, Drago F, Puzzo D, Palmeri A.  A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep. 2015; 5:11252. doi: 10.1038/srep11252.

 

72) Devroye C, Cathala A, Di Marco B, Caraci F, Drago F, Piazza PV, Spampinato U.  Central serotonin(2B) receptor blockade inhibits cocaine-induced hyperlocomotion  independently of changes of subcortical dopamine outflow. Neuropharmacology. 2015;97:329-337.

 

73) Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, Di Pietro P, Pappalardo G, Attanasio F, Chiechio S, Bagnoli S, Nacmias B, Sorbi S, Vigneri R, Rizzarelli E, Nicoletti F, Copani A. Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Front Cell Neurosci. 2015; 9:297.

 

74) Malaguarnera G, Gagliano C, Salomone S, Giordano M, Bucolo C, Pappalardo A, Drago F, Caraci F, Avitabile T, Motta M. Folate status in type 2 diabetic patients with and without retinopathy. Clin Ophthalmol. 2015; 9:1437-42. doi: 10.2147/OPTH.S77538.

 

75)  Caraci F, Pappalardo G, Basile L, Giuffrida A, Copani A, Tosto R, Sinopoli A,  Giuffrida ML, Pirrone E, Drago F, Pignatello R, Guccione S. Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. Eur J Pharmacol. 2015;764:256-63. doi: 10.1016/j.ejphar.2015.07.015.

 

76) Albert U, Brugnoli R, Caraci F, Dell'Osso B, Di Sciascio G, Tortorella A, Vampini C, Cataldo N, Pegoraro V. Italian psychiatrists' perception on cognitive  symptoms in major depressive disorder. Int J Psychiatry Clin Pract. 2015 Nov 2:1-8.

 

77) Malaguarnera M, Motta M, Vacante M, Malaguarnera G, Caraci F, Nunnari G, Gagliano C, Greco C, Chisari G, Drago F, Bertino G. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic epatiti C treated with pegylated interferon α and ribavirin. Am J Transl Res. 2015 Nov 15;7(11):2510-8.

 

78) Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W, Torrisi  SA, Giurdanella G, Piazza C, Impellizzeri AR, Gozzo L, Navarria A, Bucolo C, Nicoletti F, Palmeri A, Salomone S, Copani A, Caraci F*, Drago F*. The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice. Pharmacol Res. 2016 Apr;106:10-20. * Co-last authors.

 

79) Fisichella V, Giurdanella G, Platania CB, Romano GL, Leggio GM, Salomone S, Drago F, Caraci F, Bucolo C. TGF-β1 prevents rat retinal insult induced by amyloid-β (1-42) oligomers. Eur J Pharmacol. 2016 Feb 2. pii: S0014-2999(16)30023-1. doi: 10.1016/j.ejphar.2016.02.002. *Co-last authors.

80) Iulita MF, Caraci F, Cuello AC. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome. CNS Neurol Disord Drug Targets. 2016;15(4):434-47.

 

81) Caraci F, Kamal MA. Editorial: Linkage of CNS and Immunology with Psychology:  Searching for New Pharmacological Targets. CNS Neurol Disord Drug Targets. 2016;15(4):378-80.

 

82) Bruno V, Caraci F, Copani A, Matrisciano F, Nicoletti F, Battaglia G. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology. 2016 Apr 30. pii: S0028-3908(16)30184-8. doi: 10.1016/j.neuropharm.2016.04.044.

83) Sinopoli A, Giuffrida A, Tomasello MF, Giuffrida ML, Leone M, Attanasio F, Caraci F, De Bona P, Naletova I, Saviano M, Copani A, Pappalardo G, Rizzarelli E. The Peptidomimetic trehalose conjugated Ac-LPFFD-Th as a strong suppressor of amyloid-β oligomer formation and cytotoxicity. Chembiochem. 2016. doi: 10.1002/cbic.201600243.

84) Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C, Cantarella RA, Elia  F, Buono S, Recupero M, Romano C, Castellano S, Bosco P, Di Nuovo S, Drago F, Caraci F & Cuello AC. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal  evaluation. Alzheimers Dement. 2016;12(11):1132-1148. doi:10.1016/j.jalz.2016.05.001.

85) Castellano S, Ventimiglia A, Salomone S, Ventimiglia A, De Vivo S, Signorelli  MS, Bellelli E, Santagati M, Cantarella RA, Fazio E, Aguglia E, Drago F, Di Nuovo S, Caraci F. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational CohortStudy. CNS Neurol Disord Drug Targets. 2016;15(10):1290-1298.

86) Praticò AD, Caraci F, Pavone P, Falsaperla R, Drago F, Ruggieri M. Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas. Drug Saf Case Rep. 2015; 2(1):6.

87) Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M. Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry. 2016; 16(1):398.

88) Sinopoli A, Giuffrida A, Tomasello MF, Giuffrida ML, Leone M, Attanasio F, Caraci F, De Bona P, Naletova I, Saviano M, Copani A, Pappalardo G, Rizzarelli E. Corrigendum: Ac-LPFFD-Th: A Trehalose-Conjugated Peptidomimetic as a Strong Suppressor of Amyloid-β Oligomer Formation and Cytotoxicity. Chembiochem. 2016; 17(20):1993. doi: 10.1002/cbic.201600502.

89) Caraci F, Tascedda F, Merlo S, Benatti C, Spampinato SF, Munafò A, Leggio GM,  Nicoletti F, Brunello N, Drago F, Sortino MA, Copani A. Fluoxetine Prevents Aβ(1-42)-Induced Toxicity via a Paracrine Signaling Mediated byTransforming-Growth-Factor-β1. Front Pharmacol. 2016 Oct  25;7:389.

90) Simoni E, Caporaso R, Bergamini C, Fiori J, Fato R, Miszta P, Filipek S, Caraci F, Giuffrida ML, Andrisano V, Minarini A, Bartolini M, Rosini M. Polyamine Conjugation as a Promising Strategy To Target Amyloid Aggregation in the Framework of Alzheimer's Disease. ACS Med Chem Lett. 2016; 7(12):1145-1150.

92) Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017; 6:397. doi: 10.12688/f1000research.10233.1.

93) Caraci F, Enna SJ, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob GF, Pariante CM, Piazza PV, Yamada K, Spedding M, Drago F. A new nomenclature for classifying psychotropic drugs. Br J Clin Pharmacol. 2017, doi: 10.1111/bcp.13302.

94) Platania CBM, Fisichella V, Fidilio A, Geraci F, Lazzara F, Leggio GM, Salomone S, Drago F, Pignatello R, Caraci F*, Bucolo C*. Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases. Int J Mol Sci. 2017;18(10). *Co-last authors.

95) Caraci F, Iulita MF, Pentz R, Flores Aguilar L, Orciani C, Barone C, Romano C,  Drago F, Cuello AC. Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. Eur J Pharmacol. 2017 Dec 15;817:7-19.

96) Torrisi SA, Salomone S, Geraci F, Caraci F, Bucolo C, Drago F, Leggio GM. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D(3) Receptor Blockade. Front Pharmacol. 2017 Oct 4;8:710. doi: 10.3389/fphar.2017.00710.

97) Di Menna L, Joffe ME, Iacovelli L, Orlando R, Lindsley CW, Mairesse J, Gressèns P, Cannella M, Caraci F, Copani A, Bruno V, Battaglia G, Conn PJ, Nicoletti F. Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology. 2018;128:301-313.

98) Caraci F, Kraneveld A, Krzan M, Luca MD. Preface Drug discovery in neurodegenerative disorders: a defeat for pharmacology? Eur J Pharmacol. 2017 Dec 15;817:1. doi: 10.1016/j.ejphar.2017.11.014.

99) Caraci F, Nicoletti F, Copani A. Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease. Curr Opin Pharmacol. 2017 Dec 23;38:1-7. doi: 10.1016/j.coph.2017.12.001.

100) Caraci F, Spampinato SF, Morgese MG, Tascedda F, Salluzzo MG, Giambirtone MC,  Caruso G, Munafò A, Torrisi SA, Leggio GM, Trabace L, Nicoletti F, Drago F, Sortino MA, Copani A. Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target. Pharmacol Res. 2018 Feb 10.  pii: S1043-6618(17)31600-6. doi: 10.1016/j.phrs.2018.02.007.

101) Fresta CG, Chakraborty A, Wijesinghe MB, Amorini AM, Lazzarino G, Lazzarino G, Tavazzi B, Lunte SM, Caraci F, Dhar P, Caruso G. Non-toxic engineered carbon nanodiamond concentrations induce oxidative/nitrosative stress, imbalance of energy metabolism, and mitochondrial dysfunction in microglial and alveolar basal epithelial cells. Cell Death Dis. 2018 Feb 14;9(2):245. doi: 10.1038/s41419-018-0280-z.

102) Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, Fabbri C, Mendlewicz J, Racagni G, Kasper S, Riva MA, Drago F. International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacol Rev. 2018 Jul;70(3):475-504. doi: 10.1124/pr.117.014977.

103)  Spampinato SF, Copani A, Nicoletti F, Sortino MA, Caraci F. Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection? Front Mol Neurosci. 2018 Nov 13;11:414. doi: 10.3389/fnmol.2018.00414..

104) Caruso G, Fresta CG, Lazzarino G, Distefano DA, Parlascino P, Lunte SM, Lazzarino G, Caraci F. Sub-Toxic Human Amylin Fragment Concentrations Promote the Survival and Proliferation of SH-SY5Y Cells via the Release of VEGF and HspB5 from Endothelial RBE4 Cells. Int J Mol Sci. 2018 Nov 20;19(11). pii: E3659. doi:  10.3390/ijms19113659.

105) Caruso G*, Caraci F*, Jolivet RB*. Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. Prog Neurobiol. 2019;175:35-53. doi:10.1016/j.pneurobio.2018.12.004

* equally contributing authors

106) Caruso G, Fresta CG, Musso N, Giambirtone M, Grasso M, Spampinato SF, Merlo S, Drago F, Lazzarino G, Sortino MA, Lunte SM, Caraci F. Carnosine Prevents Aβ-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-β1. Cells. 2019 17;8(1). doi: 10.3390/cells8010064.

107) Pasquinucci L, Turnaturi R, Montenegro L, Caraci F, Chiechio S, Parenti C. Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation. Eur J Pharmacol. 2019;847:97-102. doi:10.1016/j.ejphar.2019.01.031.

108) Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019;10:49. doi: 10.3389/fpsyt.2019.00049.

109) Vicario N, Pasquinucci L, Spitale FM, Chiechio S, Turnaturi R, Caraci F, Tibullo D, Avola R, Gulino R, Parenti R, Parenti C. Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain. Mol Neurobiol. 2019;56(11):7338-7354. doi:  10.1007/s12035-019-1607-1.

110) Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, Musso N, Sanfilippo G, Tascedda F, Palmeri A, Salomone S, Drago F, Puzzo D, Leggio GM, Caraci F. Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ(1-42) Oligomers in Mice: A Key Role of Transforming Growth Factor-β1. Front Pharmacol. 2019 Jun 21;10:693. doi: 10.3389/fphar.2019.00693.

111) Caruso G, Fresta CG, Grasso M, Santangelo R, Lazzarino G, Lunte SM, Caraci F.  Inflammation as the common biological link between depression and cardiovascular diseases: Can carnosine exert a protective role? Curr Med Chem. 2019 doi: 10.2174/0929867326666190712091515.

112) Caruso G, Fresta CG, Fidilio A, O'Donnell F, Musso N, Lazzarino G, Grasso M, Amorini AM, Tascedda F, Bucolo C, Drago F, Tavazzi B, Lazzarino G, Lunte SM, Caraci F. Carnosine Decreases PMA-Induced Oxidative Stress and Inflammation in Murine Macrophages. Antioxidants (Basel). 2019; doi: 10.3390/antiox8080281.

113) Caruso G, Benatti C, Blom JMC, Caraci F*, Tascedda F*. The Many Faces of Mitochondrial Dysfunction in Depression: From Pathology to Treatment. Front Pharmacol. 2019 Sep 10;10:995. doi: 10.3389/fphar.2019.00995. * Co-last authors

114) Caraci F, Merlo S, Drago F, Caruso G, Parenti C, Sortino MA. Rescue of Noradrenergic System as a Novel Pharmacological Strategy in the Treatment of Chronic Pain: Focus on Microglia Activation. Front Pharmacol. 2019;10:1024. doi: 10.3389/fphar.2019.01024.

115) Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Lucía A, Mapstone M, Verdooner SR, Woodcock J, Lista S. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues Clin Neurosci. 2019;21(2):177-191.

116) Godos J, Ferri R, Caraci F, Cosentino FII, Castellano S, Shivappa N, Hebert JR, Galvano F, Grosso G. Dietary Inflammatory Index and Sleep Quality in Southern Italian Adults. Nutrients. 2019 Jun 13;11(6). pii: E1324. doi: 10.3390/nu11061324.

117) Godos J, Ferri R, Caraci F, Cosentino FII, Castellano S, Galvano F, Grosso G.  Adherence to the Mediterranean Diet is Associated with Better Sleep Quality in Italian Adults. Nutrients. 2019 Apr 28;11(5). pii: E976. doi: 10.3390/nu11050976.

118) Caruso G, Spampinato SF, Cardaci V, Caraci F, Sortino MA, Merlo S. β-amyloid and Oxidative Stress: Perspectives in Drug Development. Curr Pharm Des. 2019;25(45):4771-4781. doi: 10.2174/1381612825666191209115431

119) Sancassiani F, Romano F, Balestrieri M, Caraci F, Di Sciascio G, Drago F, Hardoy MC, Moro MF, Roncone R, Piras M, Preti A, Dell'Osso L, Faravelli C, Carta MG. The Prevalence of Specific Phobia by Age in an Italian Nationwide Survey: How Much Does it Affect the Quality of Life?. Clin Pract Epidemiol Ment Health. 2019 Feb 20;15:30-37. doi: 10.2174/1745017901915010030.

120) Godos J, Currenti W, Angelino D, Mena P, Castellano S, Caraci F, Galvano F, Del Rio D, Ferri R, Grosso G. Diet and Mental Health: Review of the Recent Updates on Molecular Mechanisms. Antioxidants (Basel). 2020 Apr 23;9(4):346. doi: 10.3390/antiox9040346.

121) Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, Baldacci F, Toschi N, Garaci F, Chiesa PA, Verdooner SR, Akman-Anderson L, Hernández F, Ávila J, Emanuele E, Valenzuela PL, Lucía A, Watling M, Imbimbo BP, Vergallo A, Lista S. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Front Immunol. 2020 Mar 31;11:456. doi: 10.3389/fimmu.2020.00456.

122) Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S. Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Alzheimer Precision Medicine Initiative (APMI). Neuropharmacology. 2020 May 11:108081. doi: 10.1016/j.neuropharm.2020.108081.

123) Fresta CG, Fidilio A, Lazzarino G, Musso N, Grasso M, Merlo S, Amorini AM, Bucolo C, Tavazzi B, Lazzarino G, Lunte SM, Caraci F, Caruso G. Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. Int J Mol Sci. 2020; 21(3). pii: E776. doi: 10.3390/ijms21030776.

124) Caruso G, Fresta CG, Grasso M, Santangelo R, Lazzarino G, Lunte SM, Caraci F. Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role? Curr Med Chem. 2020;27(11):1782-1800. doi: 10.2174/0929867326666190712091515.

125) Fresta CG, Fidilio A, Caruso G, Caraci F, Giblin FJ, Leggio GM, Salomone S, Drago F, Bucolo C. A New Human Blood-Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes. Int J Mol Sci. 2020 Feb 27;21(5):1636. doi: 10.3390/ijms21051636.

126) Caraci F, Coluzzi F, Marinangeli F, Mercadante S, Rinonapoli G, Romualdi P, Nicora M, Dickenson AH. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol? Curr Med Res Opin. 2020 Jun;36(6):1015-1024. doi: 10.1080/03007995.2020.1748876.

127) Castellano S, Torrent C, Petralia MC, Godos J, Cantarella RA, Ventimiglia A, De Vivo S, Platania S, Guarnera M, Pirrone C, Drago F, Vieta E, Di Nuovo S, Popovic D, Caraci F. Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study. Neuropsychiatr Dis Treat. 2020 Feb 28;16:589-595. doi: 10.2147/NDT.S224754.

128) Guerrera CS, Furneri G, Grasso M, Caruso G, Castellano S, Drago F, Di Nuovo S, Caraci F. Antidepressant Drugs and Physical Activity: A Possible Synergism in the Treatment of Major Depression? Front Psychol. 2020 May 6;11:857. doi: 10.3389/fpsyg.2020.00857.

129) Alhakamy NA, Fahmy UA, Ahmed OAA, Caruso G, Caraci F, Asfour HZ, Bakhrebah MA, N Alomary M, Abdulaal WH, Okbazghi SZ, Abdel-Naim AB, Eid BG, Aldawsari HM, Kurakula M, Mohamed AI. Chitosan Coated Microparticles Enhance Simvastatin Colon Targeting and Pro-Apoptotic Activity. Mar Drugs. 2020 Apr 24;18(4):226. doi: 10.3390/md18040226.

130) Godos J, Ferri R, Castellano S, Angelino D, Mena P, Del Rio D, Caraci F, Galvano F, Grosso G. Specific Dietary (Poly)phenols Are Associated with Sleep Quality in a Cohort of Italian Adults.

Nutrients. 2020 Apr 26;12(5):1226. doi: 10.3390/nu12051226.

131) Carta MG, Fineberg N, Moro MF, Preti A, Romano F, Balestrieri M, Caraci F, Dell'Osso L, Disciascio G, Drago F, Hardoy MC, Roncone R, Minerba L, Faravelli C, Angst J. The Burden of Comorbidity Between Bipolar Spectrum and Obsessive-Compulsive Disorder in an Italian Community Survey. Front Psychiatry. 2020;11:188. doi: 10.3389/fpsyt.2020.00188.

132) Caruso G, Musso N, Grasso M, Costantino A, Lazzarino G, Tascedda F, Gulisano M, Lunte SM, Caraci F. Microfluidics as a Novel Tool for Biological and Toxicological Assays in Drug Discovery Processes: Focus on Microchip Electrophoresis. Micromachines (Basel). 2020 Jun 15;11:E593. doi: 10.3390/mi11060593.

133) Cavedo E, Lista S, Houot M, Vergallo A, Grothe MJ, Teipel S, Zetterberg H, Blennow K, Habert MO, Potier MC, Dubois B, Hampel H. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. INSIGHT-preAD Study Group, Alzheimer Precision Medicine Initiative.Neurology. 2020; 94:e30-e41. doi: 10.1212/WNL.0000000000008696. Collaborators INSIGHT-preAD Study Group: Filippo Caraci

134) Awan ZA, Fahmy UA, Badr-Eldin SM, Ibrahim TS, Asfour HZ, Al-Rabia MW, Alfarsi A, Alhakamy NA, Abdulaal WH, Al Sadoun H, Helmi N, Noor AO, Caraci F, Almasri DM, Caruso G. The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells. Pharmaceutics. 2020;12:E597. doi: 10.3390/pharmaceutics12070597.

135) Ahmed OAA, Fahmy UA, Badr-Eldin SM, Aldawsari HM, Awan ZA, Asfour HZ, Kammoun AK, Caruso G, Caraci F, Alfarsi A, Al-Ghamdi RA, Al-Ghamdi RA, Alhakamy NA. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials (Basel). 2020;10:E1270. doi: 10.3390/nano10071270.

 

 

Anno accademico 2022/2023
VISUALIZZA GLI INSEGNAMENTI

Anno accademico 2021/2022


Anno accademico 2020/2021


Anno accademico 2019/2020


Anno accademico 2018/2019


Anno accademico 2017/2018


Anno accademico 2016/2017


Anno accademico 2015/2016

L’attività di ricerca nel corso degli ultimi dieci anni ha coperto aspetti multisciplinari della farmacologia molecolare e della farmacologia clinica con particolare attenzione allo studio delle basi neurobiologiche della depressione e della malattia di Alzheimer al fine di identificare nuovi target farmacologici e nuove strategie di neuroprotezione. L’attività di ricerca si è concentrata sia sullo studio del Transforming Growth Factor beta1, un fattore neurotrofico il cui deficit è stato dimostrato sia nella depressione che nella malattia di Alzheimer che sull’identificazione di farmaci psicotropi in grado di modulare positivamente la produzione e/o il rilascio di TGF-ß1 sia in vitro che in vivo. Nell’area della farmacologia clinica l’attivita’ di ricerca è stata focalizzata sullo studio delle interazioni farmacologiche (Progetto Nazionale Interdrugs) con particolare attenzione allo studio delle interazioni clinicamente significative in psicofarmacologia. Attualmente l’attività di ricerca è focalizzata in tre principali linee: 1) Identificazione di nuovi markers biologici per l’AD nella sindrome di Down in collaborazione con il Prof. C. Cuello (McGill  University,Canada); 2)Identificazione dei links neurobiologici tra abuso di cannabis e patogenesi della schizofrenia e ricerca di nuovi target farmacologici in collaborazione con l’INSERM U1215 Université Bordeaux, (Prof. PV Piazza); 3) Ruolo del  TGF-ß1 nella patogenesi della malattia di Alzheimer: identificazione di nuovi target farmacologici per strategie di neuro protezione (UNICT).